Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Joanne Quan Sells 7,287 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Joanne Quan sold 7,287 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $670,258.26. Following the completion of the sale, the insider owned 18,864 shares of the company’s stock, valued at $1,735,110.72. This trade represents a 27.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Joanne Quan also recently made the following trade(s):

• On Thursday, January 22nd, Joanne Quan sold 1,822 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total transaction of $170,047.26.
• On Tuesday, January 20th, Joanne Quan sold 6,911 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $90.27, for a total value of $623,855.97.

Mirum Pharmaceuticals Stock Up 4.2%

Shares of MIRM opened at $96.55 on Wednesday. Mirum Pharmaceuticals, Inc. has a 52-week low of $36.88 and a 52-week high of $109.28. The company has a market capitalization of $5.83 billion, a PE ratio of -201.14 and a beta of 0.52. The stock has a fifty day simple moving average of $96.13 and a two-hundred day simple moving average of $81.00. The company has a quick ratio of 2.55, a current ratio of 2.67 and a debt-to-equity ratio of 0.98.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The firm had revenue of $148.93 million for the quarter, compared to analyst estimates of $141.78 million. During the same period in the previous year, the firm posted $1.00 EPS. The company’s revenue was up 49.8% compared to the same quarter last year. As a group, equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Key Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum completed enrollment in the Phase 3 EXPAND study of LIVMARLI (maralixibat) for additional rare cholestatic liver diseases, a key clinical milestone that keeps the program on track; topline data are expected in Q4 2026. This is a material near‑term catalyst that can materially re‑rate the stock if results are positive. Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli Mirum Completes Enrollment (Yahoo)
• Negative Sentiment: Multiple insiders (CEO Christopher Peetz, COO Peter Radovich, CFO Eric Bjerkholt, SVP Jolanda Howe and Joanne Quan) sold meaningful blocks of shares on March 16 — collectively several million dollars at an average price of ~$91.98 — reducing their holdings by double‑digit percentages. Large, clustered insider sales can be perceived as profit‑taking or concern about near‑term upside and may put pressure on the stock even though insiders still retain significant equity. SEC filings: Peetz Form 4 Radovich Form 4 Bjerkholt Form 4 Howe Form 4 Quan Form 4

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Citizens Jmp cut their price objective on Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating for the company in a research report on Thursday, February 26th. Royal Bank Of Canada decreased their target price on shares of Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating on the stock in a research report on Thursday, February 26th. HC Wainwright lifted their price target on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Evercore set a $126.00 price target on shares of Mirum Pharmaceuticals in a research note on Wednesday, March 4th. Finally, Leerink Partners decreased their price objective on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $117.00.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Cullen Frost Bankers Inc. purchased a new position in Mirum Pharmaceuticals in the fourth quarter valued at $30,000. MCF Advisors LLC increased its holdings in Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after purchasing an additional 185 shares during the period. Eurizon Capital SGR S.p.A. purchased a new stake in Mirum Pharmaceuticals during the 4th quarter worth about $32,000. CIBC Private Wealth Group LLC acquired a new stake in Mirum Pharmaceuticals in the 4th quarter valued at about $32,000. Finally, Quantbot Technologies LP acquired a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at about $33,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.